The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y, Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H, Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L, Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R.
Makdasi E, et al. Among authors: yitzhaki s.
Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21.
Cell Rep. 2021.
PMID: 34464610
Free PMC article.